Retatrutide, Amycretin, Survodutide, VK2735, and MariTide are among the most watched pipeline assets heading into 2026 because each represents a different answer to the same commercial question: what comes after Ozempic, Wegovy, Mounjaro, and Zepbound
In this review, the mechanism of action of GLP-1 receptor agonists on glucose metabolism and on the kidney are discussed as well as the (pre)clinical data that currently are suggestive of renoprotection, and potentially involved pathways
Antioxidants work best as systems, not solo acts
The Wolverine Blend's multi-pathway approach can address several of these simultaneously
Glutathione: The King Of Antioxidants
Figuring out your best-value option The right plan is the one that's effective, tolerable, and sustainable for your budget, and that's a moving target as prices change